“Biotronik’s remote technologies are moving the industry forward. The Prospera system has been evaluated through pre-clinical and clinical work in the BENEFIT studies. This can lead to rapid return of pain, increased difficulty managing pain, decreased quality of life, together with a higher chance of therapy abandonment. Currently available technologies require patients to wait for those adjustments in person, often for prolonged periods of time, without optimized therapy. Currently, most patients require periodic stimulation adjustments and ongoing compliance to ensure their therapy remains optimized for adequate treatment. The company is touting these two features as advantages over existing SCS devices. Prospera incorporates a novel stimulation paradigm called Resonance and a patient-centric care model called Embrace One that offers automatic, objective, daily remote monitoring and ongoing management and support. The company launched a new business segment called Biotronik Neuro, based in Lake Oswego, OR, to pursue the neuromodulation market. Biotronik is a major player in the cardiac devices market, where it competes with Medtronic, Boston Scientific, and Abbott-three incumbents in the SCS space. The market for spinal cord stimulation systems got a little more crowded this month when Biotronik, the German medtech manufacturer, announced FDA approval for its Prospera system. Biotronik Announces FDA Approval of Prospera SCS System
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |